AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
AC Immune secured FDA Fast Track designation and IND clearance for ACI-7104, an active immunotherapy targeting alpha-synuclein for early-stage Parkinson's disease. The designation is supported by interim Phase 2 data from the VacSYn trial, which demonstrated safety, tolerability, and a 100% immunogenicity responder rate at 76 weeks.
Key figures
- Drug Name
- ACI-7104
- Phase Of Trial
- Phase 2
- Grant amount
- $4 million
- Immunogenicity responder rate
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.